All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Rasbelon 1.5mg Injection
Prescription Required
Salt Composition : Rasburicase
Manufacturer : CELON LABORATORIES LTD
Origin of Medicine : India
1 Vial(s)
Introduction to Rasbelon 1.5mg Injection
Rasbelon 1.5mg Injection is an antihyperuricemic drug belonging to the category of uricolytic agent, containing the active ingredient Rasburicase. It is used in the treatment of acute hyperuricemia in patients receiving chemotherapy. When cancer cells break down, they can release large amounts of uric acid into the bloodstream. This can cause hyperuricemia, which can lead to kidney damage and other health problems. Also, this medicine can be used to prevent or treat hyperuricemia in patients with tumor lysis syndrome(a large number of cancer cells die within a few periods).
In patients with G6PD deficiency, rasburicase can trigger hemolysis(destruction of RBC) by generating reactive oxygen species that damage red blood cells. As a result, Rasbelon 1.5mg Injection is generally contraindicated in patients with G6PD deficiency. If you are diagnosed with this deficiency, inform your physician before taking this medicine because you will be more likely to experience severe haemolytic anaemia or methemoglobinemia(an abnormal form of haemoglobin). Children who are undergoing chemotherapy for leukaemia, lymphoma, or solid tumor malignancies are at risk for developing hyperuricemia, which can lead to kidney damage, seizures, and other complications. This drug helps to treat hyperuricemia by rapidly reducing the levels of uric acid in the blood. It is important to closely monitor children who are receiving Rasbelon 1.5mg Injection for any signs of allergic reactions, hemolysis (breakdown of red blood cells), or any other side effects. Talk with your healthcare provider if you have kidney or liver disease, vision problems and lung problems. Your healthcare provider will check regular blood tests to prevent complications. Avoid consuming alcohol as it may cause dizziness.
Consult your doctor before using this medication if you are pregnant or plan to have a baby. Rasbelon 1.5mg Injections are unsafe to use during pregnancy as it causes harm to an unborn fetus. Your health care practitioner will conduct a pregnancy test before you start treatment with Rasbelon 1.5mg Injection. Discuss with your doctor effective birth control methods and utilise them for at least two weeks following the last dose.
Uses of Rasbelon 1.5mg Injection
- Treat high uric acid levels in chemotherapy
Therapeutic Effects of Rasbelon 1.5mg Injection
It works by converting uric acid into allantoin, a more soluble compound that can be easily excreted by the kidneys. This reduces the levels of uric acid in the blood and prevents the development of hyperuricemia.
Interaction of Rasbelon 1.5mg Injection with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Rasbelon 1.5mg Injection and reduce effectiveness by causing undesirable side effects.
More Information about Rasbelon 1.5mg Injection
- Store Rasbelon 1.5mg Injection in a refrigerator (2°C to 8°C).
- Keep it out of reach from children.
How to consume Rasbelon 1.5mg Injection
The medicine will be administered to you by a healthcare professional in a hospital setting. Rasburicase is given as an injection into a vein (intravenous infusion) over a period of 30 minutes, once a day for up to 5 days. The dose, route of administration, and frequency will be decided by your doctor based on your disease condition and other factors.
Safety Advices for Rasbelon 1.5mg Injection
Pregnancy
It is unsafe to use during pregnancy whether Rasbelon 1.5mg Injection can be taken during pregnancy. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
Breast Feeding
It is not known if Rasbelon 1.5mg Injection passes into your breast milk or if it will affect your baby. Please consult your doctor before breastfeeding.
Lungs
It is unknown whether Rasbelon 1.5mg Injection can be used for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Liver
It is unknown whether Rasbelon 1.5mg Injection can be used for patients with liver disorders. Inform your physician if you have any liver problems before starting treatment with Palonosetron.
Alcohol
Consuming alcohol may affect the effectiveness of Rasbelon 1.5mg Injection. Stop consuming alcohol if you are taking this medicine.
Driving
It is unsafe to drive vehicles or operate heavy machinery after taking the Rasbelon 1.5mg Injection because it contains a small amount of alcohol which may cause dizziness and impair your concentration.
Side Effects of Rasbelon 1.5mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious
- Swelling of face, lips, tongue
- Wheezing and breathing problems
Common
- Nausea, vomiting
- Fever
- Swelling
- Anxiety
- Headache
- Abdominal pain
- Constipation
- Diarrhea
- Low phosphate levels in the blood
- High levels of liver enzymes in the blood
- Rashes
Word of Advice
Foods that are high in purines should be avoided, such as red meat, organ meats, and some seafood, which can increase uric acid levels and reduce the effectiveness of Rasbelon 1.5mg Injection. Avoid driving and operating heavy machinery if you feel tired or weak during this treatment. Certain activities or conditions that can trigger gout attacks, such as fasting, rapid weight loss, and stress, should also be avoided while taking Rasburicase. Dehydration can reduce the effectiveness of the medication and increase the risk of side effects, so it is necessary to drink plenty of fluids, especially water, while taking this medicine. Smoking can cause oxidative stress in the body, which can lead to an increase in uric acid levels. It is advised to avoid smoking or using tobacco products while undergoing treatment with Rasbelon 1.5mg Injection.
FAQs
Q 1. What is the purpose of Rasbelon 1.5mg Injection?
Rasbelon 1.5mg Injection is used to prevent or treat hyperuricemia (high levels of uric acid in the blood) in patients who are undergoing cancer chemotherapy for leukemia, lymphoma, and solid tumor malignancies.
Q 2. Is Rasbelon 1.5mg Injection supportive therapy?
Yes, it is an important supportive therapy for patients undergoing chemotherapy to reduce the risk of complications associated with high levels of uric acid in the blood.
Q 3. Who should not use Rasbelon 1.5mg Injection?
Rasbelon 1.5mg Injection are not indicated for those who have already developed acute gout or hyperuricemia due to conditions other than cancer chemotherapy.
Q 4. What should I avoid while taking Rasbelon 1.5mg Injection?
It is advised to avoid certain medications, such as allopurinol, which is used to lower uric acid levels. Using allopurinol with Rasburicase together can reduce the effectiveness of rasburicase.
Q 5. How does Rasbelon 1.5mg Injection work?
Rasbelon 1.5mg Injection works by converting uric acid into allantoin, a more soluble compound that can be easily excreted by the kidneys. This reduces the levels of uric acid in the blood and prevents the development of hyperuricemia.
Q 6. Whether Rasbelon 1.5mg Injection helps to protect people who are at high risk for tumor lysis syndrome (TLS)?
Yes, it is often used prophylactically in individuals who are at high risk for TLS due to their cancer chemotherapy.
Fact Box of Rasbelon 1.5mg Injection
Molecule name: Rasburicase Injection | Therapeutic class: Antihyperuricemic |
Pharmacological class: Uricolytic agent | Indications: 1.Treat high uric acid levels in chemotherapy |
References
- Sanofi-aventis groupe, Electronic Medicines Compendium (EMC), [Revised on Jun 2021] [Accessed on 27th March 2023], https://www.medicines.org.uk/emc/files/pil.12870.pdf
- Sanofi-aventis U.S. LLC (no date) ELITEK., ELITEK (rasburicase) Powder for solution, for intravenous infusion. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103946s5083lbl.pdf [Accessed on 27th March 2023].
- Sanofi S.p.A, Fasturtec name of the medicinal product qualitative and quantitative, Available at: https://www.sanofi.com.sg/dam/jcr:e21c742b-05a1-4b24-9d3b-a7d4c646b3bb/143%20Fasturtec%20SG%20FAS%200718%20CCDSv6.pdf [Accessed on 27th March 2023].
- Ueng, S. (2005) Rasburicase (Elitek): A novel agent for tumor lysis syndrome, Proceedings (Baylor University. Medical Center). U.S. National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1200736/ [Accessed on27th March 2023].
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Inflammation, Immunomodulation and Hematopoiesis, pharmacotherapy of gout, 12th edition, 2011, 998.
- KD Tripathi, Essentials of Medical Pharmacology, Antirheumatoid and antigout drugs, 7th edition, 2013, 217.
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
